Zhejiang Sunflower Great Health Co (300111) Fair Value & Analysis

Healthcare · CN · Market cap 4.0B CNY

Below-average quality, and screening another 83% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥0.5600). The favourable scenario is already priced in.
• Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• The models converge in a tight band (¥0.5100 to ¥0.5600), unusually little disagreement for a valuation.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.

How to read this chart

60‑month range ¥1.87 – ¥9.43 · fair‑value band ¥0.5100 – ¥0.5600 · the ¥3.04 price screens above the ¥0.5300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 7, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhejiang Sunflower Great Health Co (300111) currently trades at ¥3.04, while our model-based Fair Value estimate is ¥0.5300, implying the stock looks roughly 82.6% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Zhejiang Sunflower Great Health Co generated revenue of 254M CNY at a net margin of -3.7%. Revenue declined 24.5% year over year. It earns a return on equity of -1.0%. The balance sheet holds a net cash position of 563M CNY. Fundamentals as of Jul 7, 2026

Our scenario range runs from ¥0.5100 (bear case) to ¥0.5600 (bull case); at ¥3.04, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -83%, 300111 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (¥0.3900) versus DCF Models (¥0.3100). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally.

Full company description

Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pneumonia, and urethritis and cervicitis; and azithromycin dispersible tablets and injections for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for the treatment of high blood pressure; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zhejiang Sunflower Great Health Co reported revenue of ¥272M in FY2025 versus ¥297M in FY2021, a compound −2.2%/yr. Reported net income was −¥4.4M in FY2025.

300111 screens 83% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.